地舒单抗应如何使用？

(denosumab) is the first approved monoclonal antibody that specifically targets RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival.

Desosumab (denosumab) has a high affinity for RANKL, preventing RANK ligands from activating RANK on the surface of osteoclasts, inhibiting osteoclast activation and development, reducing bone resorption, increasing bone density and bone strength of both cortical bone and trabecular bone, promoting bone reconstruction, and reducing the incidence of vertebral, non-vertebral and hip fractures in postmenopausal osteoporotic women.

How should denosumab be used?

Desosumab (denosumab) is used for the prevention of bone-related events in solid tumor bone metastases. It is not used for the prevention of bone-related events in patients with multiple myeloma: subcutaneous injection (upper arm, upper thigh or abdomen) 120 mg, once every 4 weeks, with calcium or vitamin D infusion to prevent hypocalcemia.

Unresectable or surgical resection of giant cell tumor of bone in adults or bone-mature adolescents may cause serious complications: subcutaneous injection, 120 mg, once every 4 weeks. In the first month of treatment, 120 mg is added on the 8th and 15th days, and calcium or vitamin D is infused to prevent hypocalcemia.

Hypercalcemia of malignant tumors: subcutaneous injection, 120 mg, once every 4 weeks. During the first month of treatment, add 120 mg on the 8th and 15th days respectively.

Hypocalcemia must be corrected before denosumab (denosumab) therapy can be initiated. For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malnutrition, small bowel resection, severe renal insufficiency), clinical monitoring of creatinine and mineral levels is required, and such patients should be instructed to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D.

The use of (denosumab) must be done under the guidance of a professional doctor, and patients must not take the medicine privately.